Hypervolemic therapy volume augmentation range

General Details:

Name:
Hypervolemic therapy volume augmentation range
Steward:
NINDS
Definition:
Range of hypervolemic therapy/volume augmentation
Registration Status:
Qualified

Permissible Values:

Data Type:
Text
Unit of Measure:
Ids:
Value Code Name Code Code System Code Description

Designations:

Designation:
Hypervolemic therapy volume augmentation range
Tags:

Designations:

Definition:
Range of hypervolemic therapy/volume augmentation
Tags:

Reference Documents:

ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Diringer MN, Bleck TP, Claude Hemphill J 3rd, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES Jr, Citerio G, Gress D, H?nggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng MY, Vergouwen MD, Wolf S, Zipfel G; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211–240. • Suarez JI, Martin RH. Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design. Neurocrit Care. 2010;13(2):263–277. • Suarez JI, Martin RH, Calvillo E, Dillon C, Bershad EM, Macdonald RL, Wong J, Harbaugh R; ALISAH Investigators. The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke. 2012;43(3):683–690. • van der Jagt M. Fluid management of the neurological patient: a concise review. Crit Care. 2016;20(1):126. • van der Jagt M, Haitsma I. An injured brain needs cooling down: no. Intensive Care Med. 2015;41(6):1129–1131

Identifiers:

Source:
NLM
Id:
XJighbO5A9X
Version:
1.1
Source:
NINDS
Id:
C54937
Version:
1
Source:
BRICS Variable Name
Id:
HyprvlmcThrpyVolmAugmntatnRng
Version: